logo

NRIX

Nurix Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.03 / 10
Netural

Fundamental score: 4.0/10 indicating modest quality. Bullish factors include Revenue-MV and Profit-MV, however risks emerge in Current assets turnover ratio and Net profit / Total profit (%).. Overall assessment: constrained.

Fundamental(4.03)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-2.65
Score2/3
Weight19.07%
1M Return11.69%
Inventory turnover ratio
Value111.00
Score3/3
Weight7.34%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight16.79%
1M Return10.80%
Profit-MV
Value0.44
Score2/3
Weight12.51%
1M Return7.79%
PB-ROE
Value1.04
Score0/3
Weight5.71%
1M Return3.56%
Current assets turnover ratio
Value0.14
Score0/3
Weight-2.29%
1M Return-1.88%
Fixed assets turnover ratio
Value1.41
Score2/3
Weight0.16%
1M Return0.12%
Asset-MV
Value-0.50
Score2/3
Weight28.54%
1M Return15.13%
Cash-MV
Value0.14
Score2/3
Weight12.53%
1M Return7.73%
Net profit / Total profit (%)
Value100.29
Score0/3
Weight-0.37%
1M Return-0.30%
Is NRIX undervalued or overvalued?
  • NRIX scores 4.03/10 on fundamentals and holds a Fair valuation at present. Backed by its -49.63% ROE, -314.90% net margin, -6.55 P/E ratio, 3.22 P/B ratio, and -5.90% earnings growth, these metrics solidify its Netural investment rating.